Nautilus Collaborates with Michael J. Fox Foundation to Study Parkinson's Disease
Nautilus Biotechnology, Weill Cornell Medicine-Qatar, WCM-Q, and The Michael J. Fox Foundation for Parkinson's Research announced a research collaboration to study the connection between the alpha-synuclein protein and Parkinson's disease. Supported by a $1.6 million research grant from MJFF, the project combines the Lashuel lab's expertise in the molecular and chemical biology of neurodegeneration with Nautilus' platform for measuring proteins and their functional variants, called proteoforms, at single-molecule resolution.
Trade with 70% Backtested Accuracy
Analyst Views on NAUT
No data
About NAUT
About the author
Nautilus (NAUT) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
